Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
3.520
-0.190 (-5.12%)
Nov 16, 2026, 4:00 PM EST - Market closed
← View all transcripts

Study update

Nov 12, 2026

Summary

Expansion adds two Astellas-sponsored CLDN18.2 pancreatic cancer studies and a phase II ATC trial. The first-line pancreatic phase III is enrolling ahead of schedule; H1 2027 follow-up is planned for the phase II study.

Operator

Welcome to the Immuneering conference call to discuss its expanded development strategy, including two new clinical collaborations with Astellas in pancreatic cancer and new company-sponsored clinical program in thyroid cancer. At this time, all participants are in listen-only mode. Following the management's prepared remarks, we will hold the Q&A session. To ensure that we have ample time to address everyone's questions, we would ask each person to limit themselves to one question and one follow-up. As a reminder, this call is being recorded today, Thursday, November 12, 2026. I would now like to turn the conference call over to Laurence Watts of the New Street Investor Relations. Please go ahead.

Laurence Watts
CEO and Founder, New Street Investor Relations

Thank you, operator. Joining us on the call today from Immuneering are Co-founder and Chief Executive Officer Ben Zeskind, Chief Scientific Officer Brett Hall, Chief Medical Officer Igor Matushansky, and Chief Financial Officer Andrew Gengos. In addition, we are delighted to have on the call Dr. Alan Ho, Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center. During this call, management will make forward-looking statements, including statements related to its clinical development plans for atebimetinib, as well as the timing of data from its own and partnered clinical development studies. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties.

Factors that could cause these results to be different from these statements include factors the company describes in its securities filings, including its annual report on Form 10-K and our quarterly reports on Form 10-Q. Immuneering undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. With that, I would like to turn the call over to Ben Zeskind, Chief Executive Officer of Immuneering. Ben?

Ben Zeskind
Co-Founder and CEO, Immuneering

Thank you, Laurence, and thank you to everyone joining us today. Today is an important day in what has already been a transformative year for Immuneering and the cancer patients we serve. At ASCO in June, we reported 17.3 months median overall survival in our ongoing phase II study in first-line pancreatic cancer, with what we believe is a potentially best-in-class tolerability profile and 84% of evaluable patients weight stable or gaining weight at three months. This was an all-comers population with no genetic testing required. These data support our aspiration to deliver long survival with outstanding quality of life in a broad population of patients. We recently announced that this trial is being extended as patients are living longer than projected on atebimetinib, and we plan to share another update in the first half of 2027.

Building on this momentum, we began dosing patients in MAPKeeper 301, our phase III registrational trial in pancreatic cancer, which is enrolling rapidly ahead of schedule and generating substantial excitement in the oncology community. With the phase III going so well, now is the time to embark on an expanded program of development, which we believe greatly increases the opportunity to create value for patients and shareholders. Today, we are announcing three important new clinical trials that illustrate the significant breadth of atebimetinib's potential. We are thrilled to be starting two new trials in collaboration with and sponsored by Astellas that will evaluate two distinct CLDN18.2-directed approaches in combination with atebimetinib in pancreatic cancer. We are also excited to announce a new phase II trial of atebimetinib in combination with chemotherapy in anaplastic thyroid cancer, or ATC. I am particularly pleased that Dr. Ho is able to join us.

His experience treating patients with anaplastic thyroid cancer will bring an important clinical perspective to our discussion. These three new trials are in addition to the phase II trial of atebimetinib in combination with Regeneron's anti-PD-1 cemiplimab, for which we expect to dose the first patient by the end of the year. Four distinct combinations in different settings with a simple unifying idea: atebimetinib has the potential to deliver long survival and outstanding quality of life to a wide set of cancer patients, and to make it possible to combine MAP kinase pathway inhibition with a broad range of other cancer treatments. Today, we will begin with the scientific and strategic foundation for our pipeline expansion, then discuss the Astellas collaborations, then turn to the thyroid cancer opportunity, including hearing from Dr. Ho. We will then open the call for questions.

As a reminder, our lead program, atebimetinib, is an oral, once-daily third-generation MEK inhibitor. We designed it to address the limitations of earlier-generation MEK inhibitors, including tolerability and resistance, while preserving the potential body mass benefits associated with MEK inhibition. The key preclinical data was recently published in Cancer Research and highlighted in a spotlight commentary. We chose the MAP kinase pathway for our first program because it plays a central role in so many solid tumors. MEK is a critical signaling node downstream of RAS and RAF, and a compelling target if you can inhibit it in a way that patients can tolerate over time. Conventional continuous inhibition can put sustained pressure on both tumor cells and healthy tissues. That pressure can contribute to toxicity and the emergence of resistance. Our Deep Cyclic Inhibition approach is different.

It is designed to deliver deep, transient pathway inhibition, followed by a recovery window. We believe that this approach may allow us to disrupt tumor signaling while limiting some of the trade-offs of chronic inhibition. There is a second strategic benefit. If atebimetinib can be combined effectively with other therapies, it can become a backbone on which to build combination regimens. We see at least six broad categories of opportunity with preclinical data that support and enable all of them. Combinations with chemotherapy are the furthest along clinically, and combinations with immunotherapies will be starting shortly in lung cancer. We chose these three new studies with an eye towards combinations that can produce fast paths to data in a capital-efficient way. The Astellas collaboration we are announcing today will explore additional targeted and immune-engaging approaches in pancreatic cancer.

Our planned ATC program extends the chemotherapy combination strategy into a different and particularly aggressive tumor type. Altogether, this is the beginning of a much more expansive clinical development strategy. With that background, let me now turn to today's first announcement, our clinical trial collaboration and supply agreement with Astellas Pharma Global Development, a subsidiary of Astellas Pharma Inc. Under this agreement, Astellas will sponsor and conduct two planned clinical studies in pancreatic cancer patients whose tumors express Claudin 18.2. Immuneering will provide atebimetinib for both studies, and the companies will each retain global development and commercialization rights for their respective investigational medicines. The first planned study will evaluate an investigational Claudin 18.2-targeted Astellas candidate added to atebimetinib, plus modified gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer.

In other words, it builds on the chemotherapy backbone that we are already studying with atebimetinib while adding a further targeted treatment modality. The second planned study is especially interesting because it will evaluate a chemotherapy-free regimen, combining atebimetinib with a different investigational Claudin 18.2-targeted Astellas program. That study is expected to include previously treated patients with metastatic pancreatic cancer. These are distinct approaches, and we should not assume that they will behave the same way clinically, which is precisely why we are excited to evaluate them. We want to learn whether the characteristics of atebimetinib can support a broad range of combinations for different patient populations. We expect to share additional study details when appropriate and in coordination with our collaborator.

Importantly, we believe this agreement is a huge vote of confidence in atebimetinib and a capital-efficient way for Immuneering to demonstrate atebimetinib's potential as a backbone treatment, thanks to its highly differentiated safety and tolerability profile. Claudin 18.2 is an emerging target in gastrointestinal oncology, including about 30% of pancreatic tumors. Its expression creates an opportunity to direct investigational therapies towards tumor cells using mechanisms distinct from MEK inhibition. For us, the strategic point is not that one combination is necessarily superior to another. It is that atebimetinib could be a flexible partner for multiple therapeutic modalities. One approach adds a Claudin 18.2-directed therapy to our existing atebimetinib and chemotherapy regimen. The other explores whether a Claudin 18.2-directed treatment can be paired with atebimetinib without chemotherapy. These studies will help us understand whether combining complementary mechanisms can improve outcomes in patients with Claudin 18.2-expressing pancreatic cancer.

We view this collaboration as further validation of the scientific interest in atebimetinib as a combination partner and as an efficient way to explore additional opportunities alongside our internally sponsored programs. Other similar discussions are ongoing, so this may be just the beginning. Now, I would like to turn to our second announcement, which takes us into a different type of cancer, anaplastic thyroid cancer, or ATC. ATC is rare, but it is one of the most aggressive cancers physicians encounter. Tumors can grow extraordinarily quickly, and patients often present with locally advanced or metastatic disease. Although targeted therapies have improved outcomes for certain molecularly defined groups, many patients still have limited options. The MAP kinase pathway is implicated in ATC, including through alterations involving BRAF and RAS, which we believe creates a strong biological rationale for studying atebimetinib in this setting, particularly in combination with chemotherapy.

In addition, the number of patients required for this planned trial is small, making it capital-efficient and enabling a fast path to a potentially registrational readout. Today, we are announcing plans for a phase II clinical study of atebimetinib plus chemotherapy in ATC. We plan to submit an IND to the FDA by the end of this year and, subject to regulatory clearance, target dosing our first patients in mid-2027. Our scientific rationale will be featured in a preclinical poster at the EORTC-NCI-AACR Symposium in Barcelona on November 18. That presentation is entitled "Atebimetinib, a Deep Cyclic Inhibitor of MEK, Combined with Chemotherapy: Preclinical Rationale for Treatment of Anaplastic Thyroid Cancer." It is abstract 144, poster PB144. We look forward to sharing those data at the meeting, and I will not preempt the scientific presentation today.

To help explain why this disease is such an important opportunity, I would now like to invite Dr. Alan Ho to share his perspective. Alan.

Alan Ho
Chief of the Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center

Thank you, Ben. It is a pleasure to join you all today. I am Dr. Alan Ho from Memorial Sloan Kettering Cancer Center. I am speaking today on behalf of an informal group of thyroid cancer experts at four leading hospitals who worked together on the plan for this study and encouraged Immuneering to conduct it. The majority of anaplastic thyroid cancer cases are driven by the MAP kinase pathway, including about 40% driven by BRAF mutations and another 33% driven by other mutations.

BRAF mutant disease is treated with a combination of a RAF inhibitor and a first-generation MEK inhibitor in the first-line setting, but unfortunately, there are no standard of care options in the second-line setting. That is the setting for one of the two arms of the trial. For the 33% driven by other MAP kinase pathway alterations, there are no approved treatments targeting the MAP kinase pathway.

For the second arm of the trial, it will also focus on the second-line setting for those patients. My colleagues and I are excited about the planned trial for multiple reasons. First, we have seen the phase II data in first-line pancreatic cancer presented at ASCO and are encouraged by the high reported overall survival in another very challenging tumor type. Second, we are familiar with both the benefits of earlier generation MEK inhibitors and their limitations, particularly tolerability. The clinical data for atebimetinib suggests it will be extremely well tolerated in our patients. Thirdly, research on pulsatile MEK inhibition in general and atebimetinib's specific preclinical data both suggest the treatment could help facilitate T-cell-mediated tumor rejection and responses for our patients.

For all these reasons, I am looking forward to being an investigator on this trial and being able to explore a promising new possibility for my patients with second-line anaplastic thyroid cancer. I know that many of my fellow key opinion leaders at top institutions likely feel the same way.

Ben Zeskind
Co-Founder and CEO, Immuneering

Thank you, Dr. Ho. We are grateful to you and to each of the investigators who helped design this study and encouraged us to pursue it. I will now ask our Chief Medical Officer, Igor Matushansky, to tell you a bit more about the study.

Igor Matushansky
Chief Medical Officer, Immuneering

Thank you, Ben. Here, you can see the design of the study, which involves second-line ATC patients with MAP kinase pathway alterations who have progressed on standard of care treatment in the first-line setting. We will be combining 320 milligram atebimetinib with carboplatin and pemetrexed chemotherapy, starting with a six-patient safety lead-in, followed by approximately 29 patients each in the two cohorts Dr. Ho described, one with BRAF mutations and one for patients without BRAF mutations. The primary endpoint is overall response rate, and secondary endpoints include DOR, DCR, PFS, safety, and OS. The study was designed in close collaboration with KOLs from four leading centers for the treatment of ATC, and we believe it has the potential to be registrational. We plan to submit an Investigational New Drug, IND, application to the U.S. Food and Drug Administration for the program by the end of this year.

Subject to regulatory clearance, we currently expect to dose the first patient in the study in mid-2027, with top-line results potentially available 12-18 months after dosing begins. I will now hand it back to Ben.

Ben Zeskind
Co-Founder and CEO, Immuneering

Thank you, Igor. We firmly believe, based on the phase II data we have presented in first-line pancreatic cancer, that atebimetinib represents an entirely new way to achieve long survival, with outstanding tolerability and in a broad all-comers population. Our highest priority is to execute MAPKeeper 301, our global phase III study of atebimetinib in combination with gemcitabine/nab-paclitaxel chemotherapy in first-line metastatic pancreatic cancer, which is enrolling ahead of schedule. The opportunity for atebimetinib extends well beyond the combination with gemcitabine/nab-paclitaxel in first-line pancreatic cancer. Today marks a turning point for Immuneering, the beginning of a new chapter focused on realizing the full potential of atebimetinib in more combinations and for more cancer patients. Today, we are adding two CLDN18.2-directed pancreatic cancer trials in collaboration with Astellas, as well as our own company-sponsored phase II program in ATC.

These build on our previously discussed plans to evaluate atebimetinib with an anti-PD-1 therapy in non-small cell lung cancer, where we plan to dose the first patient before year-end. We receive extensive inbound interest from companies and KOLs to explore atebimetinib in new combinations and new tumor types. We will be disciplined about which programs we advance and how we allocate our resources while continuing to pursue this broader strategy. Today's announcements are just the beginning. We are incredibly proud of the progress our team has made, and we are grateful to the patients, families, investigators, and collaborators who make this work possible. I would also like to once again thank Dr. Ho for joining us, and he is now going to disconnect and get back to his patients. With that, operator, we are ready to take questions.

Operator

Thank you. We will now begin the question-and-answer session. Please limit yourself to one question and one follow-up. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from Andrew Berens with Leerink Partners. Please go ahead.

Speaker 6

Hi, everyone. Good morning. This is Amanda on for Andrew. Could you maybe provide a little bit more color on the preclinical or rationale for the Claudin 18.2 collaboration? I think you called them distinct yet complementary in the press release. If I can sneak in one more, how are you thinking differently between the couple different programs or assets within their Claudin 18.2 program, if you can say at this point? Thanks.

Ben Zeskind
Co-Founder and CEO, Immuneering

Hi, Amanda. Thanks for the question. Look, we're really excited about what we're seeing in pancreatic cancer, right? The data we presented at ASCO with 17.3 months mean overall survival, outstanding quality of life in terms of both tolerability and weight stability and gain. It really establishes, we believe, atebimetinib plus gemcitabine and nab-paclitaxel as the frontrunner in first-line chemotherapy. Sorry, in first-line pancreatic cancer treatment, atebimetinib in combination with chemotherapy. The question now becomes, how do you further build on that? I think there's a set of therapies targeting specific patient subsets in pancreatic cancer. Claudin 18.2 is an important one of those, right? It's expressed on at least 30% of pancreatic cancer tumors, potentially more depending on where you draw the cutoff.

This is a really important target, and we think it's just great validation that Astellas has chosen to collaborate with us and sponsor these studies to layer their Claudin 18.2 programs on top of the atebimetinib plus gemcitabine and nab-paclitaxel combination in the first line, as well as to explore another combination in the second line. So it's a huge vote of confidence. I think it's really the clinical rationale that I think motivates this. Astellas is really a leader in the Claudin 18.2 space with multiple programs, and so we're honored that they'd like to explore multiple programs together with us. Thank you for the question.

Operator

Your next question comes from Allison Bratzel with Piper Sandler. Please go ahead.

Allison Bratzel
Analyst, Piper Sandler

Hey. Good morning, team, and thanks for taking the questions. I may have missed it, but could you just talk to when you expect each Astellas study to begin and generate initial data? Then just clarify if either of those will be controlled trials. Then just bigger picture, thinking about future collaborations, how are you prioritizing indications and combination partners or targets? Thank you.

Ben Zeskind
Co-Founder and CEO, Immuneering

Thanks, Allison. We are thrilled to be collaborating with Astellas on this. We do not want to get ahead of them in terms of announcing details of the study. Certainly, those will be available in due course, and I can tell you that both they and we are committed to getting these studies up and running for patients as quickly as possible. We will certainly be moving quickly on the timing. In terms of future collaborations, I think this is really just the beginning, right? I mean, the tolerability is the key that unlocks combinations, and atebimetinib is so well tolerated because that is fundamentally a big part of what the Deep Cyclic Inhibition technology enables, right? It is a new source of therapeutic index. It is a new way to drive outstanding quality of life together with long survival in a broad population of patients.

We think there is a wide set of combination opportunities, and we are exploring many beyond this. Certainly, we are thrilled, though, to be collaborating with Astellas on a set of programs for Claudin 18.2. It is a target that they certainly know very well, have deep expertise in, and is important in pancreatic cancer. We think this is the beginning of a broad set of combination opportunities for atebimetinib, both in pancreatic cancer and beyond. MAPK pathway is broadly applicable to many different tumor types. We are certainly excited about the future going forward, and we think these collaborations are an important step towards that future.

Operator

Your next question comes from Li Watsek with Cantor Fitzgerald. Please go ahead.

Speaker 8

Hey, good morning. This is Lubin on for Li. I have a question about the ATC trial, and maybe this is for Dr. Ho. Can you help us understand what the benchmark is here? What kind of ORR would you like to see in each cohort for this to be a meaningful clinical improvement? Thank you.

Ben Zeskind
Co-Founder and CEO, Immuneering

Yeah. Hi, Lubin. Thanks. I will take that. Dr. Ho had to get back to his patients. I think we have laid out the trial design in detail. We are excited about ATC because it is an unmet need. It is largely driven by the MAP kinase pathway. In fact, a good percentage of it is driven by BRAF. This is important. About 40% of ATC is driven by BRAF mutations. BRAF mutant patients, this is an area where first-generation MEK inhibitors have been effective in the past, albeit with tolerability challenges. BRAF mutant disease in general is a substantial opportunity for a third-generation MEK inhibitor like atebimetinib. So we are really excited to be going into BRAF mutant disease. Yet, another substantial portion of the patients is driven by RAS. So, it is really a great setting for a third-generation MEK inhibitor like atebimetinib.

It is a setting that allows us to, in a capital-efficient, rapid way, run a trial that we believe has the potential to be registrational. Unfortunately, in the settings that we are testing it in, there are really not good standard of care options. So, we are looking forward to exploring it, and certainly the responses in second line are extremely low. Unfortunately, the benchmarks are low, which means, again, this is just a huge unmet need and a real opportunity to help these patients. Thank you for the question.

Operator

Your next question comes from Andres Y. Maldonado with H.C. Wainwright. Please go ahead.

Andres Y. Maldonado
Analyst, H.C. Wainwright

Hey, everybody. Good morning. Thanks for taking my question, and congrats on the progress here. Two from us. One on the pancreatic Claudin 18.2 programs. Just trying to get a sense of, I understand that in pancreatic cancer, about 30% test positive for Claudin 18.2. But if we take a page out of the variants that we see in gastric and ovarian cancer, how variant is that expression for those tumors that express 18.2? I guess for context, can you put some color on the market there with relative to expression?

On the ATC program, one question that I would like to highlight is, since I guess the V600E cohort, I am assuming, requires progression on BRAF to MEK therapy, can you talk a little bit about the evidence that you guys have that supports overcoming that resistance with atebimetinib, and maybe some additional color on why the carbo/pemetrexed is the right backbone there? Thank you very much.

Ben Zeskind
Co-Founder and CEO, Immuneering

Great. Thanks for the questions, Andres. You are right. The 30% of pancreatic cancer patients whose tumors express Claudin 18.2, that is a particular threshold, as I mentioned. So depending on where you draw that threshold, it can actually be a larger number of patients as well. I think the important point to keep in mind is that atebimetinib plus gemcitabine/nab-paclitaxel is really applicable to all comers in pancreatic cancer. I think that is what makes this regimen so exciting. That is what makes the MAPKeeper 301 phase III clinical trial so exciting, right? There is no genetic testing required. Patients can get on this treatment regimen fast. It is broadly applicable. I think that is why, and scientifically, that is because as a third-generation MEK inhibitor, atebimetinib can block RAS mutations, RAS amplifications, BRAF mutations. It has a very wide ability to block different mutations.

That is the breadth, the all-comers nature of atebimetinib plus gem/nab. That is why we are so excited about the MAPKeeper 301 study. It is why it is enrolling ahead of schedule. That is why we have said we have extended the follow-up in our phase II study, and we are going to update on that in the first half of 2027. So a lot that is exciting there. There is a number of therapies under development in pancreatic cancer that target narrower subsets. We think that is a good thing for patients. Options are good for patients. Historically, when you have an approach that targets a specific subset, whether it is Claudin 18.2, G12C, G12D, these approaches are limited in their durability. We believe they are all going to want to combine with a broad regimen that has long survival and outstanding quality of life.

We think atebimetinib plus gem/nab is the clear combination partner of choice for essentially a wide range of these therapies that will target different patients. I think the exact numbers, we will see how they play out. Ultimately, our goal is for atebimetinib plus gem/nab to become the backbone for a wide variety of treatments targeting specific patient subsets in pancreatic cancer. This is the first exciting step in that direction. With regard to the thyroid cancer, to your second question, you are absolutely right. One of the arms of the trial is focused on BRAF V600E mutant patients who have already progressed on a first-generation MEK inhibitor plus RAF. I will just say we are extremely confident of atebimetinib's potential in that setting in combination with chemotherapy.

I do not want to get ahead of our presentation coming up on November 18, but I would encourage you to stay tuned for that. I think that will provide the most comprehensive answer to your question, and certainly, I think further add to the rationale for why we are all so excited about this study.

Operator

Your next question comes from Javier Manso with Bloomberg. Please go ahead.

Javier Manso
Analyst, Bloomberg

Hey, team. Thanks for taking my question. I just wanted to know what is your level of involvement in the trial design with Astellas? Also, kind of follow up with Andres' question, are you thinking of perhaps focusing on high expression level patients for the Claudin 18 group, or is it going to be like an all-comer situation and just kind of define the threshold yourself? Thank you.

Ben Zeskind
Co-Founder and CEO, Immuneering

Thanks, Javier. This is a close collaboration with Astellas, so we are thrilled and honored to be partnering with them. We think it is a huge vote of confidence on their part in atebimetinib as the future of first-line pancreatic cancer. This is a company that does their homework, and they do thorough diligence. They have deep expertise in pancreatic cancer in general, as well as the Claudin 18.2 as a target in general. So we collaborated closely on the study concept and the protocol. They, of course, are in charge of running the study and sponsoring it. We have very close collaboration with mechanisms that allow us to discuss and work together on it. So this is really a collaboration that we are excited about and we will be working closely together, although, of course, they ultimately are running the study and funding it, which is great.

It gives us a very capital-efficient way to explore a combination like this. Again, we believe it's a huge vote of confidence in atebimetinib. As for the details of the patient enrollment criteria, we are not going to get ahead of our collaborator on that, but I think certainly all those details will be available in due time.

Operator

There are no further questions at this time. I will now turn the call back over to Ben Zeskind for closing remarks.

Ben Zeskind
Co-Founder and CEO, Immuneering

Well, thank you, operator, and I want to thank everyone for joining us today. We look forward to updating you on the progress of MAPKeeper 301, our collaboration programs, and our planned anaplastic thyroid cancer study as we reach further milestones. Have a great day, and full speed ahead.

Operator

This completes today's call. Thank you for attending. You may now disconnect.